

Cat. 2062

ESBL Chromogenic Agar

Chromogenic medium for overnight detection of gram-negative bacteria producing Extended Spectrum Beta-Lactamase.

Aplications Categories Detection ESBL Bacteria Industry: Clinical Image: Clinical

Principles and uses

ESBL (Extended Spectrum ß-Lactamases) is a Chromogenic medium for the detection of gram-negative bacteria producing Extended Spectrum Beta-Lactamase.

ESBL (Extended Spectrum ß-Lactamases) are enzymes capable of hydrolyzing penicillins, broad-spectrum cephalosporins and monobactams, ESBLs are often located on plasmids that are transferable from strain to strain and between bacterial species. ESBL-producing Enterobacteriae were first identified in Germany in 1983, and now they are widely recognized as clinically relevant causes of infections in community. During the 1990s were mostly found in Klebsiella species. However E. coli ESBL-producing has also been widely detected and both have a significant importance in hospital acquired infections. Community-acquired urinary tract infection (CA-UTI) is the most common infection caused by extended-spectrum ß-lactamase (ESBL)-producing Enterobacteriaceae and it is a big concern in management of patients and hospital costs. The development and spread of ESBL among Gram-negative bacteria and possible horizontal transfer calls for concern, especially in view of treatment failure, high treatment cost, and consequent discomfort to patients. The early detection of ESBL-producing bacteria carriers is essential to minimize their impact and spread.

Peptones and growth factors provide nitrogen, vitamins, minerals and aminoacids essential for growth. Chromogenic mixture allows the identification of ESBL producing microorganisms. The supplement inhibits the growth of all the non ESBL-producing bacteria.

Characteristics of the ESBL colonies:

- E. coli: pink colonies.

- Enterobacter aerogenes: dark blue colonies.
- Klebsiella pneumoniae: dark blue colonies.

Formula in g/L

Bacteriological agar	16	Chromogenic mixture	3
Peptone	14	Growth factors	15

Preparation

Suspend 48,0 grams of medium in one liter of distilled water. Mix well and dissolve by heating with frequent agitation. Boil for one minute until complete dissolution. Sterilize in autoclave at 121 °C for 15 minutes. Cool to 50 °C and aseptically add two vials of ESBL supplement (Cat. 6042). Mix well and dispense into plates.

Instructions for use

For clinical diagnosis, the type of sample is urine, rectal sample and pulmonary aspiration.

- Inoculate on the surface making parallel striae with the handle or swab.

- Incubate in aerobic conditions at 35±2 °C for 18-24 hours.

Quality control

Solubility	Appareance	Color of the dehydrated medium	Color of the prepared medium	Final pH (25°C)
w/o rests	Fine powder	Beige	Amber, slightly opalescent	7,2±0,2

Microbiological test

Incubation conditions: (35±2 °C / 18-24 h).					
Microorganisms	Specification	Characteristic reaction			
Klebsiella pneumonieae ATCC 13883	Total inhibition				
Enterococcus faecalis ATCC 19433	Partially inhibited	Light blue colonies			
Escherichia coli ATCC 2469	Good growth	Pink colonies			
Escherichia coli ATCC 25922	Total inhibition				
Staphylococcus aureus ATCC 25923	Total inhibition				
Proteus mirabilis ATCC 25933	Total inhibition				

Storage

Temp. Min.:2 °C Temp. Max.:25 °C

Bibliography

Ryan S. Arnold, MD, Kerri A. Thom, MD, MS, [...], and Daniel J. Morgan, MD Emergence of Klebsiella pneumoniae Carbapenemase (KPC)-Producing Bacteria.

Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update.Clinical Microbiology Reviews. 2005;18:657–686. [PMC free article] [PubMed]

Österblad M, Kirveskari J, Koskela S, et al. First isolations of KPC-2-carrying ST258 Klebsiellapneumoniae strains in Finland, June and August 2009. Euro Surveill. 2009;14(40):19349. [PubMed] Martín Cil L, Villa FM, Rames Sánghez MC, Martín Cil F L, "Studies on beta lagtam antibiotics... Differential thermal analysis of Caphalacaering". L

Martín-Gil J, Villa FM, Ramos-Sánchez MC, Martín-Gil FJ. "Studies on beta-lactam antibiotics - Differential thermal-analysis of Cephalosporins". J. Thermal Anal Cal, 1984, 29 (6): 1351-1357.

SebastianDroguettPerez (Dr.2)(2004)*Rossi S. (Ed.) (2004). Australian Medicines Handbook 2004. Adelaide: Australian Medicines Handbook. ISBN 0-9578521-4-2.(* Rossi S (Ed.) (2004).